87 completed, 12 terminated, 12 unknown, 10 not yet recruiting. 136 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 136 | Completed 87, Terminated 12, Unknown 12, Not yet recruiting 10, Recruiting 7, Active not recruiting 4, Withdrawn 4 |
Follow Dermatitis, Atopic: new trials by email Literature Review of Dermatitis, Atopic trials Research Report on Dermatitis, Atopic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients Skin Cleanser Combination No.1 - Atopic Dermatitis | Phase 4 | Not yet recruiting | Boston Children's Hospital | 100 | 2031-01-01 | 2026-03-10 |
| Opzelura Experience Study ruxolitinib, ruxolitinib and an Eczema Action Plan - Atopic Dermatitis | Phase 4 | Not yet recruiting | Wake Forest University Health Sciences | 50 | 2026-12-01 | 2026-09-04 |
| AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes Lebrikizumab-lbkz - Atopic Dermatitis | Phase 4 | Not yet recruiting | Forefront Dermatology S.C | 250 | 2026-11-11 | 2026-10-02 |
| A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis Dupilumab - Atopic Dermatitis | Phase 4 | Not yet recruiting | Sanofi | 56 | 2026-10-28 | 2026-10-29 |
| Abrocitinib Dose Tapering in Patients With Atopic Dermatitis Abrocitinib - Atopic Dermatitis | Phase 4 | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 100 | 2026-10-01 | 2026-09-29 |
| The Impact of Dietary Salt on the Severity of Eczema Sodium chloride tablets, Placebo Tablets - Eczema, Atopic Dermatitis | Phase 4 | Recruiting | University of California, San Francisco | 40 | 2026-08-10 | 2026-09-10 |
| Azithromycin in Atopic Dermatitis Betamethasone or tacrolimus ointments, Azithromycin - Atopic Dermatitis | Phase 4 | Not yet recruiting | Cairo University | 40 | 2026-08-01 | 2026-07-20 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream. Roflumilast Cream 0.15% - ITCH, Atopic Dermatitis | Phase 4 | Recruiting | Integrative Skin Science and Research | 40 | 2026-07-21 | 2026-08-13 |
| The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease Sodium chloride tablets, Placebo Tablets - Atopic Dermatitis (Eczema), Psoriasis | Phase 4 | Recruiting | University of California, San Francisco | 50 | 2026-07-14 | 2026-09-09 |
| Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema Placebo Cream, Crisaborole 2% Cream - Atopic Dermatitis (AD), Atopic Eczema | Phase 4 | Not yet recruiting | Jinnah Postgraduate Medical Centre | 270 | 2026-03-01 | 2026-03-06 |
| Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis Crisaborole 2% Topical Application Ointment [EUCRISA, tacrolimus 0.1% - Atopic Dermatitis | Phase 4 | Not yet recruiting | Hayat Abad Medical Complex, Peshawar | 148 | 2026-03-01 | 2026-03-02 |
| Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis Application of crisaborole twice daily, Tacrolimus ointment in atopic dermatitis - Dermatitis, Atopic, Eczema | Phase 4 | Not yet recruiting | Cairo University | 30 | 2026-02-01 | 2026-01-26 |
| Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab dupilumab - Severe Atopic Dermatitis (AD) | Phase 4 | Withdrawn | Regeneron Pharmaceuticals | 2025-11-11 | 2025-11-28 | |
| Lebrikizumab in Moderate-to-severe Atopic Dermatitis lebrikizumab - Atopic Dermatitis | Phase 4 | Active not recruiting | Johann E Gudjonsson MD PhD | 48 | 2025-07-02 | 2026-09-15 |
| A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden Lebrikizumab - Atopic Dermatitis | Phase 4 | Completed | Eli Lilly and Company | 233 | 2025-06-16 | 2026-10-15 |
| Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients Dupilumab, Tofacitinib - Atopic Dermatitis | Phase 4 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 220 | 2025-01-01 | 2024-06-20 |
| Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis Dupilumab - Atopic Dermatitis, Sleep Disturbance | Phase 4 | Recruiting | Northwestern University | 40 | 2024-08-12 | 2026-04-27 |
| Dupilumab De-escalation in Pediatric Atopic Dermatitis Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose - Atopic Dermatitis | Phase 4 | Terminated | Johns Hopkins University | 1 | 2024-04-01 | 2026-11-03 |
| A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis dupilumab - Dermatitis Atopic | Phase 4 | Active not recruiting | Sanofi | 48 | 2024-02-22 | 2026-04-13 |
Showing 20 of 136. Sign in to see all of them.
Eczema (25) · Pruritus (7) · Dermatitis (6) · Psoriasis (6) · Asthma (4) · Facies (2) · Lymphoma, Follicular (2) · Rhinitis, Allergic (2) · Bronchiolitis Obliterans Syndrome (1) · Coinfection (1) · Conjunctivitis, Allergic (1) · Folliculitis (1) · Hypersensitivity (1) · Impetigo (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (136) · Genetic Diseases, Inborn (136) · Hypersensitivity, Immediate (136) · Immune System Diseases (136) · Skin Diseases (136) · Skin Diseases, Genetic (136) · Skin and Connective Tissue Diseases (136) · Hypersensitivity (135) · Skin Diseases, Eczematous (135) · Dermatitis (130) · Pathological Conditions, Signs and Symptoms (10) · Signs and Symptoms (7) · Skin Manifestations (7) · Skin Diseases, Papulosquamous (6) · Bronchial Diseases (5)
dupilumab (26) · pimecrolimus (21) · Tacrolimus (10) · crisaborole (10) · Adrenal Cortex Hormones (4) · Cyclosporine (4) · abrocitinib (4) · lebrikizumab (4) · Omalizumab (3) · Sodium Chloride (3) · montelukast (3) · retapamulin (3) · ruxolitinib (3) · tralokinumab (3) · upadacitinib (3)
Novartis (10) · Sanofi (8) · University of California, San Francisco (7) · Astellas Pharma Inc (6) · Wake Forest University Health Sciences (4) · Derm Research, PLLC (3) · Innovaderm Research Inc. (3) · Novartis Pharmaceuticals (3) · Technische Universität Dresden (3) · Wake Forest University (3) · Cairo University (2) · Casa Espirita Terra de Ismael (2) · Ceragenix Pharmaceuticals (2) · Fougera Pharmaceuticals Inc. (2) · Instituto de Investigación Hospital Universitario La Paz (2)
United States (70) · Germany (11) · Canada (8) · United Kingdom (8) · Spain (6) · Switzerland (6) · Australia (5) · Brazil (5) · China (5) · France (4) · Netherlands (4) · Finland (3) · Italy (3) · Austria (2) · Belgium (2)
Robert Bissonnette, MD (3) · Amy Paller, MD (2) · Fu-Tong Liu, M.D., Ph.D. (2) · Katrina Abuabara, MD (2) · Leon H. Kircik, M.D. (2) · Raymond Cho, MD, PhD (2)
PMID 16680006, PMID 18385500, PMID 19127072, PMID 19403473, PMID 19863501, PMID 20070141, PMID 21099191, PMID 21121981, PMID 21533301, PMID 22805051, PMID 22920495, PMID 22951056, PMID 23374261, PMID 24435467, PMID 26598458, PMID 28330497, PMID 28491950, PMID 31764962, PMID 32212104, PMID 36806068, PMID 36824052, PMID 37181420, PMID 37429687, PMID 41350756, PMID 41611123, PMID 42027418, PMID 42126851
2018 (3), 2004 (1), 2009 (1), 2023 (1), U19AI117673 (1)